RepliCel Life Sciences Inc. announced it has now received and analyzed all data and images from independent laboratory testing of the DermaPrecise injector prototype and consumables evaluating the injection systems' various depths and doses in donated human skin tissue. Human full thickness skin biopsies were injected with marker ink with viscosity matching commonly used drugs. Post-injection, the skin was cut into sections to be stained and evaluated.

The injection parameters for depth and volume showed test results meet or surpass DermaPrecise objectives for consistency of volume and depth delivery.